Home › Circulars › RBI/2013-14/567

FDI in Pharma: Non-Compete Clause Curbed

Current · Source: Reserve Bank of India · RBI/2013-14/567 · issued 21 Apr 2014 · ~2 min read
Quick answerRBI has tightened FDI rules for pharma: non-compete clauses in brownfield deals now require FIPB approval, except in special cases. Greenfield FDI remains 100% automatic; brownfield stays 100% via government route. Banks must update customers.
The rule, in the simplest words
How it plays out — a real example

A forex & trade-finance officer in Indore is processing a payment for a foreign pharma company buying an Indian drug plant. She spots a non-compete clause in the contract. Remembering the new rule, she stops the payment and tells the customer they must get FIPB approval first, saving the bank from a compliance headache.

What changed

The existing FDI policy for pharmaceuticals continues, but with a new condition: non-compete clauses are prohibited unless the Foreign Investment Promotion Board (FIPB) approves them in special circumstances. This change applies immediately from the circular date, April 21, 2014, and has been formalised through an amendment to FEMA regulations.

What it means for you

For banks handling FDI remittances in pharma, brownfield deals now carry extra compliance: any non-compete clause must be flagged for FIPB approval. This reduces flexibility for acquirers and may slow deal closures. Lenders must verify that no unapproved non-compete clauses exist in transaction documents before processing payments.

What you must do

Who it affects

AD Category-I banks processing pharma FDI, Pharmaceutical companies seeking brownfield FDI, Foreign investors in Indian pharma sector, FIPB (Foreign Investment Promotion Board)

❓ Common questions

Does this circular change the overall FDI limits for pharma?

No. The 100% automatic route for greenfield and 100% government approval route for brownfield investments remain unchanged. Only the non-compete clause condition is new.

What happens if a non-compete clause is included without FIPB approval?

Such clauses are not allowed. Banks must not process the FDI remittance unless FIPB approval for the non-compete clause is obtained. The circular makes this a mandatory condition.

Which FEMA notification implements this change?

The Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) (Amendment) Regulations, 2014, notified via Notification No. FEMA.296/2014-RB dated March 3, 2014.

📜 Read the original circular — full text as issued by RBI
RBI/2013-14/567 A.P. (DIR Series) Circular No.124 April 21, 2014 To All Category – I Authorised Dealer Banks Madam / Sir, Foreign Direct Investment in Pharmaceuticals sector – clarification Attention of Authorised Dealers Category – I (AD Category - I) banks is invited to A.P. (DIR Series) Circular No.56 dated December 9, 2011 and the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2000, notified vide Notification No. FEMA 20/2000-RB dated May 3, 2000 , as amended from time to time. In terms of Schedule 1 to the Notification ibid, Foreign Direct Investment (FDI) up to 100 per cent is permitted under automatic route for greenfield investments and FDI up to 100 per cent is permitted under Government approval route for brownfield investments (i.e. investments in existing companies) in pharmaceuticals sector. 2. The extant FDI policy for pharmaceutical sector has since been reviewed and it has now been decided with immediate effect that the existing policy would continue with the condition that ‘non-compete’ clause would not be allowed except in special circumstances with the approval of the Foreign Investment Promotion Board (FIPB) of the Government of India. 3. A copy of Press Note No.1 (2014 Series) dated January 8, 2014 issued in this regard by Department of Industrial Policy and Promotion, Ministry of Commerce & Industry, Government of India is enclosed. 4. AD Category - I banks may bring the contents of the circular to the notice of their customers/constituents concerned. 5. Reserve Bank has since amended the subject Regulations accordingly through the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident outside India) (Amendment) Regulations, 2014 which have been notified vide Notification No. FEMA.296/2014-RB dated March 3, 2014 , vide G.S.R. No. 270(E) dated April 7, 2014. 6. The directions contained in this circular have been issued under Sections 10(4) and 11(1) of the Foreign Exchange Management Act, 1999 (42 of 1999) and are without prejudice to permissions / approvals, if any, required under any other law. Yours faithfully, (C.D.Srinivasan) Chief General Manager
Reproduced for reference with acknowledgment — Source: Reserve Bank of India · RBI/2013-14/567 · issued 21 Apr 2014. The plain-English explanation above is BankPulse’s own independent summary.
🧰 Tools — save, print, templates & related
Most relevant forCorporate / Wholesale Banking RMTrade Finance / Forex OperationsCompliance TeamRM — Loans (Assets)NRI Relationship ManagerCurrent Account / Trade RM
🛠 Banker’s toolkit — checklists & reply templates →
Related circulars · Foreign Exchange (FEMA)
RBI raises cash carry limit for travellers to Rs 7,500Rupee Value of Special Currency Basket Revised to Rs.60.897378ECB Policy Liberalised: Cost Ceilings Removed, NBFCs & Realty Get BoostECB: Integrated Township Exemption Removed, Cost Ceilings TightenedRBI Delegates Bank Guarantee Powers for Foreign Airlines to AD Banks
Browse all departments →
Worked example & action-note template

Example: if you are a Compliance officer at a bank this circular applies to (AD Category-I banks processing pharma FDI, Pharmaceutical companies seeking brownfield FDI, Foreign investors in Indian pharma sector, FIPB (Foreign Investment Promotion Board)), your first concrete step on “FDI in Pharma: Non-Compete Clause Curbed” is: “Update internal FDI processing checklists to include verification of non-compete clauses in brownfield pharma deals.” (RBI issued this 21 Apr 2014).

  1. Circular: RBI/2013-14/567 -- FDI in Pharma: Non-Compete Clause Curbed
  2. Issued: 21 Apr 2014
  3. Action required: Update internal FDI processing checklists to include verification of non-compete clauses in brownfield pharma deals.
  4. Action required: Advise customers that non-compete clauses require prior FIPB approval; reject remittances without such approval.
  5. Action required: Train forex staff on the revised FEMA Notification No. FEMA.296/2014-RB dated March 3, 2014.
  6. Action required: Review existing brownfield pharma FDI cases to ensure compliance with the new condition.
  7. Owner: ____________ Target date: ____________
  8. Board/committee approval needed? Y / N
  9. Evidence filed in compliance register on: ____________
Built only from this circular’s own published fields — not legal advice; always confirm against the official RBI source.

💬 Banker Discussion

Discuss this circular with fellow bankers — reply, upvote what helps, report what doesn’t belong. Be professional; no client data. Views are the commenter’s own, not BankPulse’s.

Loading comments…
BankPulse Compliance Evidence Pack — generated 03 Aug 2026 · status cross-checked against RBI’s official withdrawal register (refreshed weekly).
Official RBI source: https://www.rbi.org.in/Scripts/NotificationUser.aspx?Id=8845&Mode=0 — Plain-English summary by BankPulse (bankpulse.ai), reviewed by our expert reviewer, CA Amit Jain. Independent platform, not affiliated with the Reserve Bank of India; is our own plain-English paraphrase, not RBI’s original wording.
Public beta — plain-English informational summaries. Always verify against the official RBI source (circular number cited on every page) before making compliance, credit, treasury, audit, or operational decisions. · Join our WhatsApp channel ↗
—